Vincent O'Brien

Summary

Affiliation: University of Glasgow
Country: UK

Publications

  1. ncbi request reprint A mutational analysis of the transforming functions of the E8 protein of bovine papillomavirus type 4
    V O'Brien
    Beatson Institute for Cancer Research, CRC Beatson Laboratories, Garscube Estate, Glasgow, G61 1BD, Scotland
    Virology 255:385-94. 1999
  2. ncbi request reprint Signalling cell cycle arrest and cell death through the MMR System
    Vincent O'Brien
    Centre for Oncology and Applied Pharmacology, Cancer Research UK Beatson Laboratories, Garscube Estate, Glasgow G61 1BD, UK
    Carcinogenesis 27:682-92. 2006
  3. ncbi request reprint The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients
    Gillian Gifford
    Centre for Oncology and Applied Pharmacology, Glasgow University, Cancer Research UK Beatson Laboratories, Glasgow, United Kingdom
    Clin Cancer Res 10:4420-6. 2004
  4. ncbi request reprint Epigenomics and epigenetic therapy of cancer
    Robert Brown
    Cancer Research UK Dept of Medical Oncology, Beatson Laboratories, Glasgow University, Glasgow, UK G61 1BD
    Trends Mol Med 8:S43-8. 2002
  5. ncbi request reprint Demethylation of DNA by decitabine in cancer chemotherapy
    Robert Brown
    Cancer Research UK Beatson Laboratories, Centre for Oncology and Applied Pharmacology, Glasgow University, Glasgow G61 1BD, UK
    Expert Rev Anticancer Ther 4:501-10. 2004
  6. ncbi request reprint Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors
    Kim Appleton
    Centre for Oncology and Applied Pharmacology, Glasgow University, Cancer Research UK Beatson Laboratories, Glasgow, United Kingdom
    J Clin Oncol 25:4603-9. 2007
  7. ncbi request reprint Critical evaluation of p53 as a prognostic marker in ovarian cancer
    Jacqueline Hall
    Centre for Oncology and Applied Pharmacology, Cancer Research UK Beatson Laboratories, University of Glasgow, Garscube Estate, Switchback Road, Bearsden, Glasgow, G61 1BD, UK
    Expert Rev Mol Med 6:1-20. 2004
  8. ncbi request reprint Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker
    Jens M Teodoridis
    Centre for Oncology and Applied Pharmacology, CRUK Beatson Laboratories, Glasgow University, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK
    Drug Resist Updat 7:267-78. 2004
  9. ncbi request reprint An exploration into study design for biomarker identification: issues and recommendations
    Jacqueline A Hall
    Centre for Oncology and Applied Pharmacology, Cancer Research UK Beatson Laboratories, University of Glasgow, Garscube Estate, Glasgow, G61 1BD, UK
    Cancer Genomics Proteomics 4:111-9. 2007
  10. ncbi request reprint Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy
    Gordon Strathdee
    Centre for Oncology and Applied Pharmacology, Cancer Research UK Beatson Laboratories, Glasgow University, Glasgow G61 1BD, UK
    Gynecol Oncol 97:898-903. 2005

Detail Information

Publications53

  1. ncbi request reprint A mutational analysis of the transforming functions of the E8 protein of bovine papillomavirus type 4
    V O'Brien
    Beatson Institute for Cancer Research, CRC Beatson Laboratories, Garscube Estate, Glasgow, G61 1BD, Scotland
    Virology 255:385-94. 1999
    ..They suggest that E8 might function differently from BPV-1 E5 and demonstrate that the separate domains of E5 and E8 are not functionally interchangeable...
  2. ncbi request reprint Signalling cell cycle arrest and cell death through the MMR System
    Vincent O'Brien
    Centre for Oncology and Applied Pharmacology, Cancer Research UK Beatson Laboratories, Garscube Estate, Glasgow G61 1BD, UK
    Carcinogenesis 27:682-92. 2006
    ..How MMR-dependent G2 arrest may link to cell death remains elusive and we speculate that it is perhaps the resolution of the MMR-dependent G2 cell cycle arrest following DNA damage that is important in terms of cell survival...
  3. ncbi request reprint The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients
    Gillian Gifford
    Centre for Oncology and Applied Pharmacology, Glasgow University, Cancer Research UK Beatson Laboratories, Glasgow, United Kingdom
    Clin Cancer Res 10:4420-6. 2004
    ..DNA methylation changes in plasma provide the potential to define patterns of methylation during therapy and identify those patient populations who would be suitable for novel epigenetic therapies...
  4. ncbi request reprint Epigenomics and epigenetic therapy of cancer
    Robert Brown
    Cancer Research UK Dept of Medical Oncology, Beatson Laboratories, Glasgow University, Glasgow, UK G61 1BD
    Trends Mol Med 8:S43-8. 2002
    ....
  5. ncbi request reprint Demethylation of DNA by decitabine in cancer chemotherapy
    Robert Brown
    Cancer Research UK Beatson Laboratories, Centre for Oncology and Applied Pharmacology, Glasgow University, Glasgow G61 1BD, UK
    Expert Rev Anticancer Ther 4:501-10. 2004
    ..Furthermore, synergistic activity with other types of investigational epigenetic therapies and existing chemotherapies opens the possibility of rational combinations and scheduling of these agents based on their biologic activity...
  6. ncbi request reprint Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors
    Kim Appleton
    Centre for Oncology and Applied Pharmacology, Glasgow University, Cancer Research UK Beatson Laboratories, Glasgow, United Kingdom
    J Clin Oncol 25:4603-9. 2007
    ..We designed a clinical study to determine the feasibility of delivering a dose of decitabine, combined with carboplatin, that would be capable of producing equivalent biologic effects in patients with solid tumors...
  7. ncbi request reprint Critical evaluation of p53 as a prognostic marker in ovarian cancer
    Jacqueline Hall
    Centre for Oncology and Applied Pharmacology, Cancer Research UK Beatson Laboratories, University of Glasgow, Garscube Estate, Switchback Road, Bearsden, Glasgow, G61 1BD, UK
    Expert Rev Mol Med 6:1-20. 2004
    ..The results from published clinical studies suggest a more complex role of p53 mutation in the mechanism of resistance in ovarian cancer than is suggested by in vitro studies...
  8. ncbi request reprint Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker
    Jens M Teodoridis
    Centre for Oncology and Applied Pharmacology, CRUK Beatson Laboratories, Glasgow University, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK
    Drug Resist Updat 7:267-78. 2004
    ....
  9. ncbi request reprint An exploration into study design for biomarker identification: issues and recommendations
    Jacqueline A Hall
    Centre for Oncology and Applied Pharmacology, Cancer Research UK Beatson Laboratories, University of Glasgow, Garscube Estate, Glasgow, G61 1BD, UK
    Cancer Genomics Proteomics 4:111-9. 2007
    ....
  10. ncbi request reprint Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy
    Gordon Strathdee
    Centre for Oncology and Applied Pharmacology, Cancer Research UK Beatson Laboratories, Glasgow University, Glasgow G61 1BD, UK
    Gynecol Oncol 97:898-903. 2005
    ..The objective of this study was to determine the extent of MCJ promoter methylation in epithelial ovarian cancer patients and address the possible role of MCJ methylation levels in response to chemotherapy in ovarian cancer patients...
  11. ncbi request reprint Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101
    Jane A Plumb
    Department of Medical Oncology, University of Glasgow, Cancer Research United Kingdom Beatson Laboratories, Glasgow, G61 1BD, United Kingdom
    Mol Cancer Ther 2:721-8. 2003
    ..Furthermore, the ability to measure histone acetylation in blood samples could provide a suitable pharmacodynamic end point to monitor drug activity...
  12. doi request reprint A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors
    Nicola L Steele
    The Beatson West of Scotland Cancer Centre, Glasgow, UK
    Clin Cancer Res 14:804-10. 2008
    ....
  13. ncbi request reprint DNA mismatch repair and Chk1-dependent centrosome amplification in response to DNA alkylation damage
    Helen M R Robinson
    Beatson Institute for Cancer Research, Glasgow, UK
    Cell Cycle 6:982-92. 2007
    ..Taken together, these results reveal novel mechanisms of cell killing by 6-TG and underscore the importance of interactions between cell cycle checkpoints and DNA MMR in determining the fate of cells bearing DNA damage...
  14. ncbi request reprint CpG island methylation of DNA damage response genes in advanced ovarian cancer
    Jens M Teodoridis
    Centre for Oncology and Applied Pharmacology, Cancer Research UK Beatson Laboratories, University of Glasgow, Glasgow, United Kingdom
    Cancer Res 65:8961-7. 2005
    ..04, n = 56). This supports the hypothesis that genetic factors affecting function of DNMT genes may underlie the propensity of tumors to acquire aberrant CpG island methylation...
  15. ncbi request reprint HOXA5 is targeted by cell-type-specific CpG island methylation in normal cells and during the development of acute myeloid leukaemia
    Gordon Strathdee
    Centre for Oncology and Applied Pharmacology, CR UK Beatson Laboratories, G61 1BD UK
    Carcinogenesis 28:299-309. 2007
    ....
  16. ncbi request reprint Epigenetic cancer therapies: DNA methyltransferase inhibitors
    Gordon Strathdee
    Cancer Research UK, Dept Medical Oncology, Beatson Laboratories, Glasgow University, Glasgow, G61 1BD, Scotland, UK
    Expert Opin Investig Drugs 11:747-54. 2002
    ..Agents that can reverse DNA methylation include nucleoside and non-nucleoside inhibitors of DNA methyltransferase. Such agents are now undergoing preclinical evaluation and clinical trials in cancer patients...
  17. ncbi request reprint Bioscience 2004
    Gordon Strathdee
    Centre for Oncology and Applied Pharmacology, Glasgow University, Cancer Research UK, Beatson Laboratories, UK
    Pharmacogenomics 5:775-8. 2004
  18. ncbi request reprint Microsatellite instability: theory and methods
    Gillian Gifford
    Department of Medical Oncology, Beatson Laboratories, Glasgow, Scotland, UK
    Methods Mol Med 97:237-50. 2004
  19. ncbi request reprint Dihydroimidazophenanthridinium (DIP)-based DNA binding agents with tuneable structures and biological activity
    Louise V Smith
    WestCHEM Department of Chemistry, Joseph Black Building, University of Glasgow, University Avenue, Glasgow, G12 8QQ, UK
    Chembiochem 7:1757-63. 2006
    ..The results provide insight into how to design biologically active DNA binding agents that can interact in these ways...
  20. ncbi request reprint Prognostic DNA methylation biomarkers in ovarian cancer
    Susan H Wei
    Human Cancer Genetics Program, Department of Molecular Virology, Immunology, and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA
    Clin Cancer Res 12:2788-94. 2006
    ..Correspondingly, distinct combinations of methylated loci can function as biomarkers for numerous clinical correlates of ovarian and other cancers...
  21. ncbi request reprint No evidence of significant silencing of Fanconi genes FANCF and FANCB or Nijmegen breakage syndrome gene NBS1 by DNA hyper-methylation in sporadic childhood leukaemia
    Stefan Meyer
    Department of Paediatric Haematology and Oncology, Central Manchester and Manchester Children s University Hospitals NHS Trust, Manchester, UK
    Br J Haematol 134:61-3. 2006
    ..This does not exclude very low levels of FANCF, FANCB or NBS1 methylation, but suggests other factors are responsible for chemo-sensitivity and chromosomal instability in sporadic childhood leukaemia...
  22. ncbi request reprint ABCB1 2677G>T/A genotype and paclitaxel pharmacogenetics in ovarian cancer
    Sharon Marsh
    Clin Cancer Res 12:4127; author reply 4127-9. 2006
  23. doi request reprint Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome
    Richard W Tothill
    Peter MacCallum Cancer Center, University of Melbourne, Melbourne, Australia
    Clin Cancer Res 14:5198-208. 2008
    ..The study aim to identify novel molecular subtypes of ovarian cancer by gene expression profiling with linkage to clinical and pathologic features...
  24. pmc Methylation Linear Discriminant Analysis (MLDA) for identifying differentially methylated CpG islands
    Wei Dai
    Ovarian Cancer Action Centre and Section of Epigenetics, Department of Oncology, Imperial College, Hammersmith Hospital, London, UK
    BMC Bioinformatics 9:337. 2008
    ..We have therefore developed a novel algorithm tailored to this type of data, Methylation Linear Discriminant Analysis (MLDA)...
  25. ncbi request reprint DNA methylation during mouse hemopoietic differentiation and radiation-induced leukemia
    George Giotopoulos
    Department of Genetics, University of Leicester, Leicester, United Kingdom
    Exp Hematol 34:1462-70. 2006
    ..To examine DNA methylation in mouse hemopoiesis before and after in vivo exposure to a leukemogenic dose of x-rays, and address whether methylation levels are associated with the relative radiosensitivity of tissues in vivo...
  26. doi request reprint CpG island methylator phenotype (CIMP) in cancer: causes and implications
    Jens M Teodoridis
    Department of Oncology, Imperial College, Hammersmith Campus, London, UK
    Cancer Lett 268:177-86. 2008
    ..Therefore, further clinical testing of the diagnostic and prognostic value of the current CIMP markers, as well as increasing our understanding of the molecular causes underlying CIMP are required...
  27. ncbi request reprint Chk1 is required for G2/M checkpoint response induced by the catalytic topoisomerase II inhibitor ICRF-193
    Helen M R Robinson
    Cell Cycle 6:1265-7. 2007
  28. pmc Identification of novel high-frequency DNA methylation changes in breast cancer
    Jared M Ordway
    Orion Genomics, St Louis, Missouri, United States of America
    PLoS ONE 2:e1314. 2007
    ....
  29. ncbi request reprint Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis
    Gordon Strathdee
    Centre for Oncology and Applied Pharmacology, Cancer Research UK
    Clin Cancer Res 13:5048-55. 2007
    ..We aimed to study the role of DNA methylation as an inducer of HOX gene silencing in leukemia...
  30. pmc A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors
    Mirjam T Epping
    Division of Molecular Carcinogenesis and Center for Biomedical Genetics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
    Proc Natl Acad Sci U S A 104:17777-82. 2007
    ..These experiments identify the RA pathway as a rate-limiting target of HDACI and suggest strategies to enhance the therapeutic efficacy of HDACI...
  31. ncbi request reprint Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer
    Sharon Marsh
    Washington University School of Medicine, Division of Oncology, St Louis, MO 63110, USA
    J Clin Oncol 25:4528-35. 2007
    ....
  32. ncbi request reprint The epigenetics of ovarian cancer drug resistance and resensitization
    Curtis Balch
    Medical Sciences, Indiana University, Bloomington, Ind, USA
    Am J Obstet Gynecol 191:1552-72. 2004
    ..Moreover, when used in combination with conventional chemotherapeutic agents, epigenetic-based therapies may provide a means to resensitize ovarian tumors to the proven cytotoxic activities of conventional chemotherapeutics...
  33. ncbi request reprint Dual repair modulation reverses Temozolomide resistance in vitro
    Vincent A Barvaux
    Paterson Institute for Cancer Research and Christie Hospital, Manchester, United Kingdom
    Mol Cancer Ther 3:123-7. 2004
    ..The increased sensitization is not observed in matched MMR proficient cells...
  34. ncbi request reprint Acquired resistance to cytolysis of the E1B-attenuated adenovirus, dl1520, in ovarian tumour cell lines
    Young T Kim
    Department of Obstetrics and Gynecology, Korea University Anam Hospital, Korea
    Cancer Gene Ther 10:589-90. 2003
  35. ncbi request reprint Multiple markers for melanoma progression regulated by DNA methylation: insights from transcriptomic studies
    William M Gallagher
    Department of Pharmacology, University College Dublin, Ireland
    Carcinogenesis 26:1856-67. 2005
    ..Overall, our data support the hypothesis that multiple genes are targeted, either directly or indirectly, by DNA hypermethylation during melanoma progression...
  36. ncbi request reprint Highly stable phenanthridinium frameworks as a new class of tunable DNA binding agents with cytotoxic properties
    Alexis D C Parenty
    Department of Chemistry, The University of Glasgow, Joseph Black Building, UK
    J Med Chem 48:4504-6. 2005
    ..The DIP framework is particularly tunable due to the flexible synthetic methodology. Furthermore, the central moiety has proved to be very stable to hydrolysis and reduction compared to other phenanthridinium-based agents...
  37. ncbi request reprint Aberrant DNA methylation in ovarian cancer: is there an epigenetic predisposition to drug response?
    Susan H Wei
    Department of Pathology and Anatomical Sciences, Ellis Fischel Cancer Center, University of Missouri School of Medicine, Columbia, Missouri 65203, USA
    Ann N Y Acad Sci 983:243-50. 2003
    ..Methylation profiles of ovarian cancer might be useful for early cancer detection and prediction of chemotherapy outcome in a clinical context...
  38. ncbi request reprint Epigenetic inactivation of MCJ (DNAJD1) in malignant paediatric brain tumours
    Janet C Lindsey
    Northern Institute for Cancer Research, The Medical School, University of Newcastle, Newcastle upon Tyne, United Kingdom
    Int J Cancer 118:346-52. 2006
    ....
  39. ncbi request reprint Development of nonsymmetrical 1,4-disubstituted anthraquinones that are potently active against cisplatin-resistant ovarian cancer cells
    Klaus Pors
    Department of Pharmaceutical and Biological Chemistry, The School of Pharmacy, University of London, 29 39 Brunswick Square, London
    J Med Chem 48:6690-5. 2005
    ..8 and its chloropropyl analogue 13 retained significant activity against human A2780/cp70 xenografted tumors in mice...
  40. ncbi request reprint Interactions of the DNA mismatch repair proteins MLH1 and MSH2 with c-MYC and MAX
    Mary Mac Partlin
    Department of Medical Oncology, Glasgow University, UK
    Oncogene 22:819-25. 2003
    ..The effect on HGPRT mutation rate is small (2-3-fold), but is consistent with deregulated c-MYC expression partially inhibiting MMR activity...
  41. ncbi request reprint DNA methyltransferase inhibitors and the development of epigenetic cancer therapies
    Frank Lyko
    Division of Epigenetics, Deutsches Krebsforschungszentrum, Im Neuenheimer Feld, Heidelberg, Germany
    J Natl Cancer Inst 97:1498-506. 2005
    ....
  42. ncbi request reprint Hypermethylation of 18S and 28S ribosomal DNAs predicts progression-free survival in patients with ovarian cancer
    Michael W Y Chan
    Human Cancer Genetics Program, Department of Molecular Virology, Immunology, and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Clin Cancer Res 11:7376-83. 2005
    ..The aim of the study was to determine the methylation status of two rDNA subunits, the 18S and 28S genes, in ovarian tumors and to correlate methylation levels with clinicopathologic features in a cohort of ovarian cancer patients...
  43. ncbi request reprint Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers
    Susan H Wei
    Department of Pathology and Anatomical Sciences, Ellis Fischel Cancer Center, University of Missouri, Columbia, Missouri 65203, USA
    Clin Cancer Res 8:2246-52. 2002
    ..The purpose of this study was to profile methylation alterations of CpG islands in ovarian tumors and to identify candidate markers for diagnosis and prognosis of the disease...
  44. ncbi request reprint The dl1520 virus is found preferentially in tumor tissue after direct intratumoral injection in oral carcinoma
    Stephen Morley
    Department of Plastic Surgery, Wythenshawe Hospital, Manchester, UK
    Clin Cancer Res 10:4357-62. 2004
    ..We also wanted to ascertain whether the virus has any macroscopic effect on normal tissue...
  45. doi request reprint Matrix stiffness and serum concentration effects matrix remodelling and ECM regulatory genes of human bone marrow stem cells
    Dimitris Karamichos
    University College London, Tissue Repair and Engineering Centre, Institute of Orthopaedics and Musculoskeletal Sciences, Stanmore, Middlesex, UK
    J Tissue Eng Regen Med 2:97-105. 2008
    ..To take into account the increasing stiffness of the matrix as increasing ECM is deposited, it would be necessary to take mechanical stimulation into account to determine predictable cellular responses...
  46. pmc High-throughput gene discovery in the rat
    Todd E Scheetz
    Center for Bioinformatics and Computational Biology, The University of Iowa, Iowa City, Iowa 52242, USA
    Genome Res 14:733-41. 2004
    ..Complete information, including radiation hybrid mapping data, is also maintained locally at http://genome.uiowa.edu/clcg.html. All of the sequences described in this article have been submitted to the dbEST division of the NCBI...
  47. ncbi request reprint Mechanical signals and IGF-I gene splicing in vitro in relation to development of skeletal muscle
    Umber Cheema
    Institute of Orthopaedics and Musculo Skeletal Science, University College London, Middlesex, United Kingdom
    J Cell Physiol 202:67-75. 2005
    ..These data indicate the importance of seeking to understand the physiological signals that determine the ratios of splice variants of some growth factor/tissue factor genes in the early stages of development of skeletal muscle...
  48. ncbi request reprint Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy
    Javier Vaquero
    Northwestern University Feinberg School of Medicine, 303 East Chicago Avenue, Chicago, IL 60611, USA
    Liver Transpl 11:1581-9. 2005
    ..In view of the high 30-day survival rate after LT, future studies of the impact of intracranial hypertension should also focus on long-term neurological recovery from ALF...
  49. ncbi request reprint The dl1520 virus is found preferentially in tumor tissue after direct intratumoral injection in oral carcinoma
    Scott Wadler
    Clin Cancer Res 11:2781-2; author reply 2782. 2005
  50. ncbi request reprint What does PET imaging add to conventional staging of head and neck cancer patients?
    Surjeet Pohar
    Department of Radiation Oncology, SUNY Upstate Medical University, Syracuse, NY, USA
    Int J Radiat Oncol Biol Phys 68:383-7. 2007
    ..To determine the value of PET scans in the staging of patients with head and neck carcinoma...
  51. ncbi request reprint Improved validation of peptide MS/MS assignments using spectral intensity prediction
    Shaojun Sun
    Department of Computer Science and Engineering, University of Colorado at Denver and Health Sciences Center, Denver, Colorado 80217 3364, USA
    Mol Cell Proteomics 6:1-17. 2007
    ....
  52. ncbi request reprint Multi-organ transplantation: is there a protective effect against acute and chronic rejection?
    Laura J Pinderski
    Division of Cardiology, Department of Medicine, University of Alabama, Birmingham, Alabama 35294 0006, USA
    J Heart Lung Transplant 24:1828-33. 2005
    ..This study was undertaken to evaluate acute and chronic heart and/or lung rejection in the setting of multiple-transplanted organs from the same donor compared with single-organ transplantation...
  53. doi request reprint ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy
    Sharon E Johnatty
    Queensland Institute of Medical Research, Brisbane, Queensland, Australia
    Clin Cancer Res 14:5594-601. 2008
    ..Although the functional consequences of ABCB1 polymorphisms have been the subject of numerous studies, few have assessed the association with clinical outcome...